Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation

Sponsor
Mayo Clinic (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05371470
Collaborator
(none)
200
1
2
24
8.3

Study Details

Study Description

Brief Summary

The purpose of this study is to learn if a voice analysis smartphone app which detects anxiety and depression could be used along with cardiac rehabilitation to improve results compared to cardiac rehabilitation alone.

Condition or Disease Intervention/Treatment Phase
  • Device: Ellipsis Health Voice Application
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Evaluation of Voice Analysis Technology in Detecting and Managing Depression and Anxiety in Patients Undergoing Cardiac Rehabilitation
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cardiac rehabilitation plus voice analysis

Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care and utilize a voice analysis smartphone app.

Device: Ellipsis Health Voice Application
Smartphone application that utilizes voice biomarkers to assess for potential presence and severity of depression and anxiety

No Intervention: Cardiac rehabilitation only

Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care.

Outcome Measures

Primary Outcome Measures

  1. Change in depressive symptoms [Baseline, 12 weeks]

    Measured using the self-reported Patient Health Questionnaire-9 (PHQ-9) to assess for major depressive disorder. Possible score range from 0 to 27, with higher scores indicating a worse outcome/greater severity of depressive symptoms.

  2. Change in anxiety symptoms [Baseline, 12 weeks]

    Measured using the self-reported Generalized Anxiety Disorder 7-Item Scale (GAD-7) that assesses anxiety symptoms. Possible score range from 0 to 21, with higher scores indicating a worse outcome/greater severity of anxiety symptoms.

  3. Change in perceived stress [Baseline, 12 weeks]

    Measured using the self-reported Perceived Stress Scale-14 (PSS-14), a 14 item questionnaire which assesses the degree to which situations in life are stressful within the last month. Each item is scored on a 5 point Likert scale from 0 (never) to 4 (very often), higher total scores indicate a worse outcome/greater severity of perceived stress.

  4. Change in quality of life [Baseline, 12 weeks]

    Measured using the self-reported abbreviated generic Quality of Life Scale developed through the World Health Organization (WHOQOL-BREF) questionnaire that assesses an individual's perceptions of their health and well-being within the last two weeks. Each item is scored on a 5 point Likert scale, higher scores indicate greater perceived quality of life.

  5. Change in health behaviors [Baseline, 12 weeks]

    Measured using the self-reported Current Health Behaviors (HB) questionnaire, a 13 item questionnaire which assesses behaviors and life circumstances during the last month. Each item is scored on a 10 point Likert scale, higher scores indicate better outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosed myocardial infarction (MI).

  • Enrolled in cardiac rehabilitation program to start within 4 weeks from hospital discharge due to MI.

  • Owns a smartphone.

  • Willing to download and use a smartphone app.

  • Able to read, write, and speak English.

Exclusion Criteria:
  • Pregnancy.

  • Actively treated for an anxiety or depressive disorder through psychotherapy or pharmacologic treatments.

  • Cardiac transplant.

  • Active substance use.

  • Neurocognitive disorder.

  • Active psychosis.

  • Mania diagnosis.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic in Rochester Rochester Minnesota United States 55905

Sponsors and Collaborators

  • Mayo Clinic

Investigators

  • Principal Investigator: Amir Lerman, MD, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Amir Lerman, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT05371470
Other Study ID Numbers:
  • 21-012982
First Posted:
May 12, 2022
Last Update Posted:
Jul 8, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Amir Lerman, Principal Investigator, Mayo Clinic
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 8, 2022